{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:23:59Z","timestamp":1785151439325,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pbb.2026.174217","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T13:51:56Z","timestamp":1779630716000},"page":"174217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence"],"prefix":"10.1016","volume":"265","author":[{"given":"Simone","family":"Lista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ballerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"L\u00f3pez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayvan","family":"Khoramipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P.","family":"Imbimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Santos-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Minoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2026.174217_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pbb.2026.174217_bb0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1037\/pha0000620","article-title":"Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice","volume":"31","author":"Allingbjerg","year":"2023","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0020","first-page":"136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights","volume":"13","author":"Alves","year":"2025","journal-title":"Med. Sci. (Basel)"},{"key":"10.1016\/j.pbb.2026.174217_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2026.174217_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pbb.2026.174217_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2025.07.001","article-title":"Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens","author":"Aran\u00e4s","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/17581869.2025.2536998","article-title":"GLP-1 agonists: a game changer in pain treatment and addiction","volume":"15","author":"Bade","year":"2025","journal-title":"Pain Manag."},{"key":"10.1016\/j.pbb.2026.174217_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2026.174217_bb0055","first-page":"112","article-title":"Socioeconomic disparities and self-reported substance abuse-related problems","volume":"10","author":"Baptiste-Roberts","year":"2018","journal-title":"Addict. Health"},{"key":"10.1016\/j.pbb.2026.174217_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2021.105834","article-title":"Changes in temporal discounting, hedonic hunger, and food addiction during recovery from substance misuse","volume":"169","author":"Basso","year":"2022","journal-title":"Appetite"},{"key":"10.1016\/j.pbb.2026.174217_bb0065","first-page":"472","article-title":"Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists","volume":"27","author":"Beauregard","year":"2024","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.pbb.2026.174217_bb0070","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0075","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/oby.21200","article-title":"Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation","volume":"23","author":"van Bloemendaal","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pbb.2026.174217_bb0080","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"10.1016\/j.pbb.2026.174217_bb0085","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.pbb.2026.174217_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review \u2013 glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pbb.2026.174217_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.actpsy.2025.105322","article-title":"Exploring boundaries with food, substances, and people in substance use recovery: a qualitative analysis","volume":"259","author":"Champagne-Langabeer","year":"2025","journal-title":"Acta Psychol."},{"key":"10.1016\/j.pbb.2026.174217_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1RAs: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"JAAPA"},{"key":"10.1016\/j.pbb.2026.174217_bb0105","doi-asserted-by":"crossref","first-page":"9710","DOI":"10.3390\/ijms21249710","article-title":"Brain site-specific inhibitory effects of the GLP-1 analogue exendin-4 on alcohol intake and operant responding for palatable food","volume":"21","author":"Colvin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0110","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0115","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3390\/biomedicines13123079","article-title":"Added value to GLP-1 receptor agonist: intermittent fasting and lifestyle modification to improve therapeutic effects and outcomes","volume":"13","author":"Cozma","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.pbb.2026.174217_bb0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tem.2012.11.008","article-title":"Glucagon-like peptide 1 and appetite","volume":"24","author":"Dailey","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbb.2026.174217_bb0140","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2026.174217_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2026.174217_bb0150","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2337\/dc15-2706","article-title":"Discordance between central (brain) and pancreatic action of exenatide in lean and obese subjects","volume":"39","author":"Eldor","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pbb.2026.174217_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2026.174217_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112466","article-title":"GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity","volume":"42","author":"Falk","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.pbb.2026.174217_bb0170","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1038\/s41598-022-17190-3","article-title":"Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use","volume":"12","author":"Farokhnia","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2026.174217_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13211","article-title":"The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: findings from human laboratory experiments and a post-mortem brain study","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pbb.2026.174217_bb0180","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.pbb.2026.174217_bb0185","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/dom.13827","article-title":"Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: implications for plateauing weight loss in response to anti-obesity therapies","volume":"21","author":"Farr","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/02791072.2012.662092","article-title":"The obesity epidemic and food addiction: clinical similarities to drug dependence","volume":"44","author":"Fortuna","year":"2012","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.pbb.2026.174217_bb0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13722-024-00481-7","article-title":"Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder","volume":"19","author":"Freet","year":"2024","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.pbb.2026.174217_bb0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13722-025-00618-2","article-title":"Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol","volume":"20","author":"Freet","year":"2025","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.pbb.2026.174217_bb0205","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001145","article-title":"Glucagon-like peptide-1 receptor agonists: a novel indication for substance use disorders?","author":"Ftiha","year":"2025","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.pbb.2026.174217_bb0210","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/healthcare13080868","article-title":"Malnutrition in substance use disorders: a critical issue in their treatment and recovery","volume":"13","author":"Garc\u00eda-Estrada","year":"2025","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.pbb.2026.174217_bb0215","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/obr.12221","article-title":"Reward processing in obesity, substance addiction and non-substance addiction","volume":"15","author":"Garc\u00eda-Garc\u00eda","year":"2014","journal-title":"Obes. Rev."},{"key":"10.1016\/j.pbb.2026.174217_bb0220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/10826084.2018.1536722","article-title":"Explaining excessive weight gain during early recovery from addiction","volume":"54","author":"Gottfredson","year":"2019","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.pbb.2026.174217_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2022.100017","article-title":"Kappa-opioid receptor activation reinstates nicotine self-administration in mice","volume":"2","author":"Gowrishankar","year":"2022","journal-title":"Addict. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0230","article-title":"Is addiction the next frontier for GLP-1 receptor agonists?","author":"Healey","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0235","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2026.174217_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2026.174217_bb0245","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0250","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0255","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1037\/adb0000870","article-title":"Co-occurrence of food addiction, obesity, problematic substance use, and parental history of problematic alcohol use","volume":"37","author":"Hoover","year":"2023","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.pbb.2026.174217_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0265","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrn3105","article-title":"Common cellular and molecular mechanisms in obesity and drug addiction","volume":"12","author":"Kenny","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0270","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1126\/science.adj2537","article-title":"GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans","volume":"385","author":"Kim","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.pbb.2026.174217_bb0275","article-title":"GLP-1 RA medication associations with hazardous alcohol drinking reductions in patients with overweight or obesity: a prospective observational study","author":"King","year":"2025","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0280","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0285","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1556\/2006.2020.00033","article-title":"Co-occurrences of substance use and other potentially addictive behaviors: epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study","volume":"9","author":"Kotyuk","year":"2020","journal-title":"J. Behav. Addict."},{"key":"10.1016\/j.pbb.2026.174217_bb0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.afos.2023.09.001","article-title":"Illicit drug use is associated with lower bone mineral density and bone strength","volume":"9","author":"Krishnamoorthy","year":"2023","journal-title":"Osteoporos. Sarcopenia"},{"key":"10.1016\/j.pbb.2026.174217_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2025.105512","article-title":"Curbing the appetites and restoring the capacity for satisfaction: the impact of GLP-1 agonists on the reward circuitry","volume":"4","author":"Krupa","year":"2025","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.pbb.2026.174217_bb0300","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1080\/10826084.2022.2107670","article-title":"Differential associations between weight status (obesity, overweight, and underweight) and substance use in young adulthood","volume":"57","author":"Lanza","year":"2022","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.pbb.2026.174217_bb0305","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/bph.15797","article-title":"Linking drug and food addiction via compulsive appetite","volume":"179","author":"Laque","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0310","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/ijerph22121819","article-title":"Post-cessation weight gain across smoking cessation therapies: a review of secondary analyses from the ZESCA, EVITA, and E3 trials","volume":"22","author":"Leli\u00e8vre","year":"2025","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.pbb.2026.174217_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-Centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pbb.2026.174217_bb0320","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2741\/4618","article-title":"Food addiction: a common neurobiological mechanism with drug abuse","volume":"23","author":"Lindgren","year":"2018","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.pbb.2026.174217_bb0325","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","article-title":"Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice","volume":"49","author":"Liu","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.pbb.2026.174217_bb0330","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.3390\/ijms26157239","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling: making the case for a functionally Gs protein-selective GPCR","volume":"26","author":"Lymperopoulos","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0335","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0340","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-025-06989-3","article-title":"Modulating reward circuits through GLP-1 signaling: implications for behavioral and substance addictions","author":"Martinelli","year":"2025","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2026.174217_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male Wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114656","article-title":"Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1","volume":"190","author":"Marzook","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0360","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5051","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","volume":"11","author":"Merkel","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.pbb.2026.174217_bb0365","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fendo.2017.00127","article-title":"Overlapping neural endophenotypes in addiction and obesity","volume":"8","author":"Michaud","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.pbb.2026.174217_bb0370","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1523\/JNEUROSCI.0115-14.2014","article-title":"Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA\/kainate signaling","volume":"34","author":"Mietlicki-Baase","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0375","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pbb.2026.174217_bb0380","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0385","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"issue":"Suppl. 4","key":"10.1016\/j.pbb.2026.174217_bb0390","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2022.119744","article-title":"Hypothalamic interaction with reward-related regions during subjective evaluation of foods","volume":"264","author":"Ogawa","year":"2022","journal-title":"Neuroimage"},{"key":"10.1016\/j.pbb.2026.174217_bb0400","article-title":"Glucagon-like peptide 1 receptor agonists in substance use disorders: a systematic review of ClinicalTrials.Gov","volume":"23","author":"Patil","year":"2026","journal-title":"Addict. Behav. Rep."},{"key":"10.1016\/j.pbb.2026.174217_bb0405","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.gastha.2024.07.006","article-title":"Cannabinoids block fat-induced incretin release via CB1-dependent and CB1-independent pathways in intestinal epithelium","volume":"3","author":"Perez","year":"2024","journal-title":"Gastro. Hep. Adv."},{"key":"10.1016\/j.pbb.2026.174217_bb0410","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41387-025-00397-4","article-title":"Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy","volume":"15","author":"Peri","year":"2025","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.pbb.2026.174217_bb0415","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.pbb.2026.174217_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314899","article-title":"Glucagon-like peptide-1 receptor in the human hypothalamus is associated with body mass index and colocalizes with the anorexigenic neuropeptide nucleobindin-2\/Nesfatin-1","volume":"23","author":"Psilopanagioti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0425","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2026.174217_bb0430","doi-asserted-by":"crossref","first-page":"32385","DOI":"10.1038\/s41598-025-17927-w","article-title":"A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity","volume":"15","author":"Quddos","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2026.174217_bb0435","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1038\/s41598-021-83116-0","article-title":"Alterations in reward network functional connectivity are associated with increased food addiction in obese individuals","volume":"11","author":"Ravichandran","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2026.174217_bb0440","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/biom15030408","article-title":"Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss","volume":"15","author":"Reiss","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.pbb.2026.174217_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.pbb.2026.174217_bb0450","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.pbb.2026.174217_bb0455","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ajpath.2025.05.025","article-title":"Alcohol-mediated skeletal muscle adaptations and their impact on comorbidities","volume":"196","author":"Rodr\u00edguez-Graciani","year":"2026","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.pbb.2026.174217_bb0460","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.nut.2011.11.003","article-title":"Prevalence of malnutrition and nutritional risk factors in patients undergoing alcohol and drug treatment","volume":"28","author":"Ross","year":"2012","journal-title":"Nutrition"},{"key":"10.1016\/j.pbb.2026.174217_bb0465","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/scipharm93020026","article-title":"Oral small-molecule GLP-1 receptor agonists: mechanistic insights and emerging therapeutic strategies","volume":"93","author":"Sald\u00edvar-Cer\u00f3n","year":"2025","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.pbb.2026.174217_bb0470","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/met.2018.0088","article-title":"The role of glucagon-like peptide-1 in energy homeostasis","volume":"17","author":"Salehi","year":"2019","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.pbb.2026.174217_bb0475","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pbb.2026.174217_bb0480","first-page":"30","article-title":"Obesity and substance misuse: is there a relationship?","volume":"10","author":"Sansone","year":"2013","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0485","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ADM.0000000000001347","article-title":"The efficacy of GLP-1 agonists in treating substance use disorder in patients: a scoping review","volume":"18","author":"Shen","year":"2024","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061965","article-title":"Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward","volume":"8","author":"Shirazi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2026.174217_bb0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.biopsycho.2017.05.001","article-title":"Role of addiction and stress neurobiology on food intake and obesity","volume":"131","author":"Sinha","year":"2018","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.pbb.2026.174217_bb0500","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.pbb.2026.174217_bb0505","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2026.174217_bb0510","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.pbb.2026.174217_bb0515","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2026.174217_bb0520","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2021.12.064","article-title":"A mouse model of weight gain after nicotine withdrawal","volume":"588","author":"Takeda","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.pbb.2026.174217_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1557691","article-title":"Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database","volume":"16","author":"Tao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0530","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2337\/dc15-0772","article-title":"Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes","volume":"39","author":"Ten Kulve","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pbb.2026.174217_bb0535","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cmet.2023.01.004","article-title":"The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes","volume":"35","author":"Thomas","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.pbb.2026.174217_bb0540","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2026.174217_bb0545","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2013.81","article-title":"A common biological basis of obesity and nicotine addiction","volume":"3","author":"Thorgeirsson","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2026.174217_bb0555","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/08901171241234136","article-title":"Impact of weight concern on post-cessation weight management, smoking cessation, and program engagement","volume":"38","author":"Toyon","year":"2024","journal-title":"Am. J. Health Promot."},{"key":"10.1016\/j.pbb.2026.174217_bb0560","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0565","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","article-title":"Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists","volume":"6","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.pbb.2026.174217_bb0570","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2026.174217_bb0575","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.pbb.2026.174217_bb0580","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","article-title":"Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents","volume":"103","author":"Vall\u00f6f","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pbb.2026.174217_bb0585","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","article-title":"Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents","volume":"149","author":"Vall\u00f6f","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0590","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41398-020-00923-1","article-title":"Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats","volume":"10","author":"Vall\u00f6f","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pbb.2026.174217_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0b013e3181ce38e7","article-title":"The treatment of obesity and its co-occurrence with substance use disorders","volume":"4","author":"Vanbuskirk","year":"2010","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0600","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neubiorev.2020.11.006","article-title":"Nutritional and metabolic alterations arising from stimulant use: a targeted review of an emerging field","volume":"120","author":"Verdejo-Garcia","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2026.174217_bb0605","article-title":"The potential role of GLP-1 receptor agonists in substance use disorders \u2013 a systematic review","volume":"16","author":"Volker","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2026.174217_bb0610","first-page":"1","article-title":"Food and drug reward: overlapping circuits in human obesity and addiction","volume":"11","author":"Volkow","year":"2012","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0615","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pbb.2026.174217_bb0620","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2026.174217_bb0625","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/ajcn\/nqz007","article-title":"Effect of acute \u03949-tetrahydrocannabinol administration on subjective and metabolic hormone responses to food stimuli and food intake in healthy humans: a randomized, placebo-controlled study","volume":"109","author":"Weltens","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.pbb.2026.174217_bb0630","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0635","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2026.174217_bb0640","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.pbb.2026.174217_bb0645","first-page":"1029","article-title":"Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes","volume":"31","author":"Wu","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.pbb.2026.174217_bb0650","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3390\/ijms26062741","article-title":"Impact of glucagon-like peptide-1 receptor agonists on mental illness: evidence from a Mendelian randomization study","volume":"26","author":"Xiang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0655","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.pbb.2026.174217_bb0660","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/acschemneuro.8b00601","article-title":"Shared behavioral and neurocircuitry disruptions in drug addiction, obesity, and binge eating disorder: focus on group I mGluRs in the mesolimbic dopamine pathway","volume":"10","author":"Yohn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2026.174217_bb0665","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2026.174217_bb0675","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.pbb.2026.174217_bb0680","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2026.174217_bb0685","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2021.711750","article-title":"Glucagon-like peptide-1 agonist exendin-4 facilitates the extinction of cocaine-induced condition place preference","volume":"15","author":"Zhu","year":"2021","journal-title":"Front. Syst. Neurosci."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305726000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305726000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:33:47Z","timestamp":1781080427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305726000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":137,"alternative-id":["S0091305726000729"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2026.174217","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2026.174217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"174217"}}